ArticleNature communications2026
Face aging rate quantifies change in biological age to predict cancer outcomes.
Article in Nature communications, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Chronological age predicts cancer survival but does not capture differences in biological aging rates. We apply FaceAge, an artificial intelligence algorithm that predicts biological age from a facial photograph, to serial clinical facial photographs to calculate the Face Aging Rate (FAR; change in FaceAge divided by the time between photographs). We analyze data from 2276 cancer patients receiving radiation therapy, using photographs captured during routine care. Higher FAR is associated with worse overall survival in stratified analyses of cohorts with the following intervals between photographs: short 10-365 days (adjusted hazard ratio [aHR] and 95% confidence interval: 1.25 [1.03-1.51]), mid 366-730 days (aHR: 1.37 [1.00-1.86]), and long 731-1,460 days (aHR: 1.65 [1.22-2.22]) after adjustment for time between photographs, sex, race, and diagnosis. FAR provides additional prognostic information beyond single time-point measures of FaceAge. FAR is a non-invasive prognostic biomarker that captures dynamic changes in biological aging.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.